Evolution of Treatment for Diabetic Nephropathy: Historical Progression from RAAS Inhibition and Onward

References

• . American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2002 2002; 25( suppl 1):S85–S89
   Web of Science ®Google Scholar
• . Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047–1053
   PubMed Web of Science ®Google Scholar
• . Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 1976; 36(4):383–388
   PubMedGoogle Scholar
• . Mogensen CE. High blood pressure as a factor in the progression of diabetic nephropathy. Acta Med Scand Suppl. 1976; 602:29–32
   PubMedGoogle Scholar
• . Mogensen CE. Antihypertensive treatment inhibiting the progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1980; 602:103–108
   Google Scholar
• . Mogensen CE. Long-term antihypertensive treatment (over six years) inhibiting the progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1981; 242:31–32
   PubMedGoogle Scholar
• . Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J. 1982; 285(6343): 685–688
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982; 285(6343):685–688
   Google Scholar
• . Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Investig. 1986; 77(6):1925–1930
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20):1456–1462
   PubMed Web of Science ®Google Scholar
• . Klahr S, Levey AS, Beck GJ, . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994; 330(13):877–884
   PubMed Web of Science ®Google Scholar
• . Levey AS, Greene T, Beck GJ, . Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1999; 10(11):2426–2439
   PubMed Web of Science ®Google Scholar
• . Maschio G, Alberti D, Janin G, . Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15):939–945
   PubMed Web of Science ®Google Scholar
• . Locatelli F, Carbams IR, Maschio G, . Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. 1997; 63:S63–S66
   Google Scholar
• . Ruggenenti P, Pema A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis. 2000; 35(6):1155–1165
   PubMedGoogle Scholar
• . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997; 349(9069):1857–1863
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Pema A, Gherardi G, . Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354(9176):359–364
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Pema A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998; 352(9136):1252–1256
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Pema A, Loriga G, ; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet. 2005; 365(9463):939–946
   PubMed Web of Science ®Google Scholar
• . Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G. Prevention and treatment of diabetic nephropathy: The program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol. 2005; 16( suppl 1):S48–S52
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR, ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Berl T, Hunsicker LG, Lewis JB, ; Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005; 16(7):2170–2179
   PubMedGoogle Scholar
• . de Zeeuw D, Remuzzi G, Parving HH, . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004; 65(6):2309–2320
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D, . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Weir MR, Shanifar S, ; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med. 2003; 163(13):1555–1565
   PubMed Web of Science ®Google Scholar
• . Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003; 26( suppl 1):S94–S98
   PubMedGoogle Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13( suppl 1):1–68
   PubMedGoogle Scholar
• . Mauer M, Zinman B, Gardiner R, . Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009; 361(1):40–51
   PubMed Web of Science ®Google Scholar
• . Clinicaltrials.gov. VA NEPHRON-D: Diabetes in Nephropathy Study. http://www.clinicaltrials.gov/ct2/show/NCT00555217?term=nephron-d&rank=1. Accessed October 20, 2011
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011; 34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4(3):542–551
   PubMedGoogle Scholar
• . Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418–424
   PubMed Web of Science ®Google Scholar
• . Jessup M, Abraham WT, Casey DE, . 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119(14):1977–2016
   PubMed Web of Science ®Google Scholar
• . Pitt B, Williams G, Remme W, . The EPHESUS trial: Eplerenone in patients with heart failure to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001; 15(1):79–87
   PubMedGoogle Scholar
• . Pitt B, Zannad F, Remme WJ, Cody R, . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–717
   PubMed Web of Science ®Google Scholar
• . Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008; 118(16):1643–1650
   PubMedGoogle Scholar
• . ; ACCORD Study GroupCushman WC, Evans GW, Byington RP, . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575–1585
   PubMed Web of Science ®Google Scholar
• . Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al.Effects intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . Pepine CJ, Handberg EM, Cooper-DeHoff RM, ; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003; 290(21):2805–2816
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Hughes S. INVEST: Mortality hazard with lowest blood pressures in diabetics with CAD? http://www.theheart.org/article/1055859.do. Accessed August 10, 2010
   Google Scholar
• . Cooper-DeHoff RM, Gong Y, Handberg EM, . Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010; 304(1):61–68
   PubMed Web of Science ®Google Scholar
• . Haller H, Ito S, Izzo JL Jr, ; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364(10):907–917
   PubMed Web of Science ®Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: Comparison with the DCCT. Diabetes Res Clin Pract. 1998; 42(2):77–83
   PubMedGoogle Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000; 321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes—United States and Puerto Rico, 1996–2007. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5942a2.htm. Accessed October 29, 2010
   Google Scholar
• . Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010; 55(5):928–940
   PubMed Web of Science ®Google Scholar
• . Mauer SM, Steffes MW, Ellis EN, Sutherland De, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Investig. 1984; 74(4):1143–1155
   PubMed Web of Science ®Google Scholar
• . Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989; 38(9):1077–1081
   PubMed Web of Science ®Google Scholar
• . Bassols A, Massagué J. Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Bio Chem. 1988; 263(6):3039–3045
   PubMedGoogle Scholar
• . Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999; 10(4):790–795
   PubMed Web of Science ®Google Scholar
• . Yener S, Comlekci A, Akinci B, . Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones (Athens, Greece). 2008; 7(1):70–76
   PubMedGoogle Scholar
• . Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993; 90(5):1814–1818
   PubMed Web of Science ®Google Scholar
• . Sharma K, Ziyadeh FN, Alzahabi B, . Increased renal production of transforming growth factor-beta 1 in patients with type II diabetes. Diabetes. 1997; 46(5):854–859
   PubMed Web of Science ®Google Scholar
• . Bobik A. Hypertension, transforming growth factor-beta, angiotensin II and kidney disease. J Hyperten. 2004; 22(7):1265–1267
   PubMedGoogle Scholar
• . Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension. 2000; 36(4):517–522
   PubMedGoogle Scholar
• . Derhaschnig U, Shehata M, Herkner H, . Increased levels of transforming growth factor-beta1 in essential hypertension. Am J Hypertens. 2002; 15(3):207–211
   PubMedGoogle Scholar
• . Ziyadeh FN, Hoffman BB, Han DC, . Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000; 97(14):8015–8020
   PubMed Web of Science ®Google Scholar
• . Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45(4):522–530
   PubMed Web of Science ®Google Scholar
• . Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens. 2003; 16(7):604–611
   PubMedGoogle Scholar
• . August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl. 2003; 87:S99–S104
   Google Scholar
• . Zhu S, Liu Y, Wang L, Meng QH. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008; 23(9):2841–2846
   PubMedGoogle Scholar
• . Dang H, Geiser AG, Letterio JJ, . SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995; 155(6):3205–3212
   PubMed Web of Science ®Google Scholar
• . Meulmeester E, Ten Dijke P. The dynamic roles of TGF-ß in cancer. J Pathol. 223(2):205–218
   PubMedGoogle Scholar
• . Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hapatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol. 2002; 13(1):96–107
   PubMedGoogle Scholar
• . Yang J, Dai C, Liu Y. Systematic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Therapy. 2001; 8(19):1470–1479
   PubMedGoogle Scholar
• . Schievenbusch S, Strack I, Scheffler M, . Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis. Mol Ther. 2010; 18(7):1302–1309
   PubMedGoogle Scholar
• . Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol. 2004; 15(10):2637–2647
   PubMed Web of Science ®Google Scholar
• . Schievenbusch S, Strack I, Scheffler M, . Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts. Biochem Biophys Res Commun. 2009; 385(1):55–61
   PubMed Web of Science ®Google Scholar
• . Mou S, Wang Q, Shi B, Gu L, Ni Z. Hepatocyte growth factor suppresses transforming growth factor-beta-1 and type III collagen in hyman primary renal fibroblasts. Kaohsiung J Med Sci. 2009; 25(11):577–587
   PubMed Web of Science ®Google Scholar
• . Homsi E, Janino P, Amano M, Saraiva Camara NO. Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury. Am J Nephrol. 2009; 29(4):283–291
   PubMed Web of Science ®Google Scholar
• . Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci. 2008; 13:7072–7086
   PubMed Web of Science ®Google Scholar
• . Nakamura S, Morishita R, Moriguchi A, . Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens. 1998; 16(12 pt 2):2019–2026
   PubMedGoogle Scholar
• . Kulseng B, Børset M, Espevik T, Sundan A. Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetol. 1998; 35(2):77–80
   PubMedGoogle Scholar
• . Katsura Y, Okano T, Noritake M, . Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care. 1998; 21(10):1759–1763
   PubMedGoogle Scholar
• . Clifford SC, Czapla K, Richards FM, O'Donoghue DJ, Maher ER. Hepatocyte growth factor-stimulated renal tubular mitogenesis: Effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Br J Cancer. 1998; 77(9):1420–1428
   PubMedGoogle Scholar
• . Miyata Y, Ashida S, Nakamura T, . Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. Biochem Biophys Res Commun. 2003; 302(4):892–897
   PubMed Web of Science ®Google Scholar
• . Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 1996; 7(11):1513–1523
   PubMedGoogle Scholar
• . Li Y, Lal B, Kwon S, . The scatter factor/hepatocyte growth factor: C-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 2005; 65(20):9355–9362
   PubMedGoogle Scholar
• . Grotendorst GR. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997; 8(3):171–179
   PubMedGoogle Scholar
• . Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol. 1996; 107(3):404–411
   PubMed Web of Science ®Google Scholar
• . Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002; 4(8):599–604
   PubMed Web of Science ®Google Scholar
• . Weston BS, Wahab NA, Mason RM. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J Am Soc Nephrol. 2003; 14(3):601–610
   PubMed Web of Science ®Google Scholar
• . Chen Y, Abraham DJ, Shi-Wen X, . CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell. 2004; 15(12):5635–5646
   PubMed Web of Science ®Google Scholar
• . Ito Y, Aten J, Bende RJ, . Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998; 53(4):853–861
   PubMed Web of Science ®Google Scholar
• . Nguyen TQ, Tarnow L, Jorsal A, . Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 2008; 31(6):1177–1182
   PubMedGoogle Scholar
• . Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007; 21(12):3355–3368
   PubMedGoogle Scholar
• . Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107(9):1058–1070
   PubMed Web of Science ®Google Scholar
• . Miyata T, Ueda Y, Horie K, . Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int. 1998; 53(2):416–422
   PubMed Web of Science ®Google Scholar
• . Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 1999; 22(9):1543–1548
   PubMed Web of Science ®Google Scholar
• . Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: A marker of coronary artery disease activity in type 2 diabetic patients. Heart. 2001; 85(1):87–91
   PubMed Web of Science ®Google Scholar
• . Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism. 2000; 49(8):1030–1035
   PubMedGoogle Scholar
• . Hammes HP, Alt A, Niwa T, . Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999; 42(6):728–736
   PubMed Web of Science ®Google Scholar
• . Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 1995; 38(4):387–394
   PubMed Web of Science ®Google Scholar
• . Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994; 91(24):11704–11078
   PubMed Web of Science ®Google Scholar
• . Bolton WK, Cattran DC, Williams ME, ; ACTION 1 Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004; 24(1):32–40
   PubMed Web of Science ®Google Scholar
• . Freedman BI, Wuerth JP, Cartwright K, . Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999; 20(5):493–510
   PubMedGoogle Scholar
• . Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003; 419(1):31–40
   PubMed Web of Science ®Google Scholar
• . Voziyan PA, Hudson BG. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci. 2005; 1043:807–816
   Google Scholar
• . Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007; 27(6):605–614
   PubMed Web of Science ®Google Scholar
• . Alperin M. New life for troubled kidney disease drug. U.S. 1 Newspaper. Reprinted from August 26, 2009. http://www.princetoninfo.com/index.php?option=com_us1more&Itemid=6&key=08-26-09%20nephrogenex. Accessed August 30, 2011
   Google Scholar
• . Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra JR, García-Bulnes G, Salas-Ramírez M, Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol. 1995; 43(2):116–121
   PubMed Web of Science ®Google Scholar
• . Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients—a randomized, equivalent trial. Clin Nephrol. 2005; 64(2):91–97
   PubMedGoogle Scholar
• . Navarro JF, Mora C, Rivero A, . Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis. 1999; 33(3):458–463
   PubMed Web of Science ®Google Scholar
• . Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail. 2003; 25(3):465–470
   PubMed Web of Science ®Google Scholar
• . Navarro JF, Mora C, Muros M, García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol. 2005; 16(7):2119–2126
   PubMed Web of Science ®Google Scholar
• . Sogno I, Vannini N, Lorusso G, . Anti-angiogenic activity of a novel class of chemopreventive compounds: Oleanic acid terpenoids. Recent Results Cancer Res. 2009; 181:209–212
   PubMedGoogle Scholar
• . Pergola PE, Krauth M, Huff JW, . Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011; 33(5):469–476
   PubMed Web of Science ®Google Scholar
• . Pergola PE, Raskin P, Toto RD, ; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011; 365(4):327–336
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON). http://www.clinicaltrials.gov/show/NCT01351675. Updated October 14, 2011. Accessed August 30, 2011
   Google Scholar